Close Menu

Gilead Sciences

The agreement is part of Biocartis' long term plans to expand its presence in the oncology field by building a menu of tests for immunotherapies.

Miles to Go

Technology Review maps out where new gene therapies for cancer patients are available, noticing an urban-rural divide.

The lead investigators said that Foundation Medicine's NGS test will enable the beginning of targeted treatment within seven days of diagnosis. 

Lasker Honorees

The Albert and Mary Lasker Foundation has announced this year's recipients of its prizes honoring basic and clinical research.

NEW YORK (GenomeWeb) – The Yale School of Medicine today said that it and Gilead Sciences have extended a research collaboration to identify the genetic and molecular bases of cancer.

NEW YORK (GenomeWeb News) – Cancer Genetics today announced that Gilead Sciences has selected it to provide clinical trial services and molecular profiling of chronic lymphocytic leukemia patients.

NEW YORK (GenomeWeb News) – SomaLogic, New England Biolabs, and Gilead Sciences are suing Enzymatics in federal court for patent infringement.

This story originally ran on Dec. 22.
By Adam Bonislawski

Gilead is funding up to $100 million to the collaboration, which is aimed at identifying new molecular targets for the development of new cancer treatments.

Movers & Shakers: Jan 7, 2011

Premium

Leroy Hood, Samuel Broder, Mark Velleca, Paul Beresford, Dino DiCamillo

The Guardian reports that some UK physicians are calling for increased regulation of direct-to-consumer genetic tests.

US tax agency says 23andMe's genetic health test can be claimed as a medical expense for tax purposes, the Wall Street Journal reports.

Two Democratic lawmakers argue at USA Today that independent science is under attack by the Trump Administration.

In PLOS this week: networks of genes co-expressed in depression, role of minichromosome maintenance genes in lung adenocarcinoma, and more.